Inactive Instrument

Diffusion Pharmaceuticals Inc Stock Other OTC

US76132G1058

End-of-day quote Other OTC Other stock markets
- ^USD	-

23-08-17	Diffusion Pharmaceuticals Inc.(NasdaqCM:DFFN) dropped from NASDAQ Composite Index	CI
23-08-16	CervoMed Completes Merger with EIP Pharma	MT

Latest news : Diffusion Pharmaceuticals Inc

23-08-17	Diffusion Pharmaceuticals Inc.(NasdaqCM:DFFN) dropped from NASDAQ Composite Index	CI
23-08-16	CervoMed Completes Merger with EIP Pharma	MT
23-08-15	EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. in a reverse merger transaction.	CI
23-08-15	Diffusion Pharmaceuticals Shareholders Approve Merger With EIP Pharma; Shares Rise	MT
23-08-08	Diffusion Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-07-31	Diffusion Pharmaceuticals Inc. Appoints Jill Davidson as A Director of the Company, Effective July 26, 2023	CI
23-05-19	Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO	CI
23-05-15	Diffusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-17	Top Premarket Gainers	MT
23-03-30	Diffusion Pharmaceuticals, EIP Pharma Agree to Merge to Create New Combined Entity	MT
23-03-29	EIP Pharma, Inc. entered into a definitive merger agreement to acquire Diffusion Pharmaceuticals Inc. for $22.2 million in a reverse merger transaction.	CI
23-02-16	Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023	CI
22-12-16	Diffusion Pharmaceuticals Enters Reaches Deal With LifeSci Special Opportunities Master Fund on Board Nominees	MT

More news

Analysts' recommendations: Diffusion Pharmaceuticals Inc

22-08-16	HC Wainwright Upgrades Diffusion Pharmaceuticals to Buy From Neutral; Price Target is $9.50	MT
20-11-17	DIFFUSION PHARMACEUTICALS : HC Wainwright Downgrades Diffusion Pharmaceuticals to Neutral from Buy	MT

More recommendations

Press Releases: Diffusion Pharmaceuticals Inc

23-12-20	Diffusion Pharma : CervoMed Corporate Presentation December 2023	PU
23-08-15	Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma	AQ
23-08-14	Diffusion Pharmaceuticals : EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies - Form 8-K	PU
23-08-09	Diffusion Pharmaceuticals : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION - Form 8-K	PU
23-08-03	Diffusion Pharmaceuticals : EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference - Form 8-K	PU

More press releases

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body's ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's intractable and difficult-to-treat conditions, including hypoxic solid tumors, such as GBM. TSC is the therapeutic candidate specifically designed to enhance the oxygen diffusion process. By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system. Hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.

Employees

Sector

More about the company